Freeline Therapeutics(FRLN) - 2022 Q1 - Quarterly Report

Exhibit 99.1 Freeline Reports Full Year 2021 Financial Results and Business Highlights Phase 1/2 programs on track in Hemophilia B and Gaucher disease and accelerated in Fabry disease Extended financial runway and streamlined organization support Company through key data readouts across all three clinical programs Strengthened leadership team with appointment of Chief Medical Of icer and recent addition of Chief Scientific Of icer LONDON, March 31, 2022 – Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (t ...